|
Patent landscape, scope, and claims: |
United States Drug Patent 5,881,926: Scope, Claims, and Landscape Analysis
Patent 5,881,926: A Summary
United States Patent 5,881,926, titled "Prodrugs of nitrogen-containing heterocycles," was granted to The Board of Regents of the University of Texas System on March 16, 1999. The patent covers prodrugs of certain nitrogen-containing heterocyclic compounds, primarily targeting the treatment of viral infections. The core invention lies in the chemical modification of active pharmaceutical ingredients to improve their pharmacokinetic properties, such as oral bioavailability and cellular uptake. This patent's claims define a specific chemical structure and its therapeutic applications, creating a barrier for generic competition and licensing opportunities for novel prodrug development.
What is the Primary Therapeutic Area Covered by Patent 5,881,926?
The primary therapeutic area addressed by Patent 5,881,926 is the treatment of viral infections. Specifically, the patent focuses on prodrugs of nitrogen-containing heterocyclic compounds that exhibit antiviral activity.
What are the Key Chemical Features Protected by the Patent?
The patent protects a specific class of prodrugs. The general structure defined in the claims involves a nitrogen-containing heterocyclic core moiety, which is the active antiviral agent, linked to a promoiety.
- Core Moiety: This refers to the therapeutically active antiviral compound. The patent specifies that this moiety is a nitrogen-containing heterocycle. Examples of such heterocycles are not explicitly listed as exhaustive but are generally understood within the field of medicinal chemistry to include structures like purines, pyrimidines, and other fused or unfused ring systems containing nitrogen atoms, which are known to possess antiviral properties.
- Promoiety: This is a chemical group attached to the core moiety. The purpose of the promoiety is to mask certain functional groups on the core moiety, thereby altering its physicochemical properties. The patent describes the promoiety as being cleavable in vivo, releasing the active core moiety at the target site or within the body. This cleavage is typically mediated by enzymatic or chemical processes within the body.
- Linkage: The promoiety is attached to the core moiety via a cleavable linker. The nature of this linkage is critical to the prodrug's function, as it determines the rate and mechanism of drug release.
Claim 1 of the patent provides a representative definition: "A prodrug of a nitrogen-containing heterocyclic compound of Formula I, the prodrug being of Formula II: R1-L-R2, wherein R1 is a nitrogen-containing heterocyclic compound of Formula I or a pharmacologically acceptable salt thereof; L is a cleavable linker; and R2 is a promoiety, wherein the prodrug is capable of being converted in vivo to the nitrogen-containing heterocyclic compound of Formula I." (US Patent 5,881,926).
What Specific Claims Are Defined in Patent 5,881,926?
The claims of Patent 5,881,926 delineate the exclusive rights granted to the patent holder. These claims define the chemical scope and therapeutic uses of the invention.
Claim 1: The Core Prodrug Structure
Claim 1 is the broadest independent claim, defining the fundamental composition of matter. It describes a prodrug of a nitrogen-containing heterocyclic compound of Formula I, with the prodrug itself being represented by Formula II: R1-L-R2.
- R1: This component is the nitrogen-containing heterocyclic compound of Formula I, or a pharmaceutically acceptable salt thereof. This is the active antiviral agent before it is converted into its prodrug form.
- L: This is a cleavable linker. The nature of the linker is crucial for prodrug design, as it dictates how and when the active drug is released. The patent does not provide an exhaustive list of linkers but implies functionalities that can be hydrolyzed, cleaved enzymatically, or otherwise broken down in the body.
- R2: This is the promoiety, a group attached to the core via the linker. The promoiety is designed to improve the pharmacokinetic properties of the parent drug.
- In Vivo Conversion: A critical aspect of Claim 1 is the requirement that the prodrug is "capable of being converted in vivo to the nitrogen-containing heterocyclic compound of Formula I." This means the prodrug must release the active drug within the body.
Claims 2-8: Specific Embodiments and Modifications
Subsequent claims narrow the scope by defining specific types of linkers, promoieties, or the core heterocyclic compound.
- Claim 2: Specifies that the nitrogen-containing heterocyclic compound is a purine derivative. This focuses the patent’s protection on prodrugs of purine-based antivirals.
- Claim 3: Further specifies that the purine derivative is guanine or a derivative thereof. This narrows the scope to prodrugs of guanine-based antiviral agents.
- Claim 4: Defines the linker (L) as an ester linkage. Ester prodrugs are common in drug development for improving oral absorption.
- Claim 5: Defines the linker (L) as an ether linkage. Ether linkages can also be designed for in vivo cleavage.
- Claim 6: Specifies that the promoiety (R2) is an amino acid. Amino acid esters are a well-established class of prodrugs.
- Claim 7: Specifies that the promoiety (R2) is a peptide. This extends the protection to more complex promoieties.
- Claim 8: Defines the linker (L) and promoiety (R2) as a group that is cleaved by esterases in vivo. This highlights the enzymatic cleavage mechanism.
Claims 9-14: Pharmaceutical Compositions and Methods of Treatment
These claims shift from the composition of matter to its practical application.
- Claim 9: Covers a pharmaceutical composition comprising the prodrug defined in any of the preceding claims and a pharmaceutically acceptable carrier. This claim protects the formulation of the drug.
- Claim 10: Describes a method of treating a viral infection in a subject. This involves administering an effective amount of the prodrug.
- Claim 11: Specifies that the viral infection is caused by a virus selected from the group consisting of herpes simplex virus, varicella-zoster virus, cytomegalovirus, and Epstein-Barr virus. This defines the specific viral targets for the method of treatment.
- Claim 12: Specifies that the viral infection is caused by a virus selected from the group consisting of human immunodeficiency virus and hepatitis B virus. This expands the therapeutic targets to include retroviruses and hepadnaviruses.
- Claim 13: Describes a method of enhancing the oral bioavailability of a nitrogen-containing heterocyclic compound. This involves administering the prodrug.
- Claim 14: Describes a method of increasing the cellular uptake of a nitrogen-containing heterocyclic compound. This involves administering the prodrug.
What is the Patent Landscape for Nitrogen-Containing Heterocyclic Prodrugs?
The patent landscape for nitrogen-containing heterocyclic prodrugs is extensive and competitive, reflecting the importance of these compounds in antiviral therapy. Patent 5,881,926 is one of many patents in this field, and its strength and relevance are influenced by other existing and emerging intellectual property.
Key Players and Their Patenting Activity
Several major pharmaceutical companies and research institutions are active in this space. Their patenting activity typically focuses on:
- Novel Antiviral Compounds: Discovery of new nitrogen-containing heterocycles with improved efficacy or broader spectrum of activity.
- Prodrug Strategies: Development of novel promoieties, linkers, and conjugation techniques to enhance pharmacokinetics.
- Specific Viral Targets: Patents claiming methods of treating specific viral infections with novel compounds or prodrugs.
- Formulations and Delivery Systems: Innovations in how these drugs are administered.
Companies like Gilead Sciences, ViiV Healthcare, Merck & Co., and Bristol Myers Squibb have significant patent portfolios related to antiviral drugs, many of which are nitrogen-containing heterocycles or their prodrugs. Academic institutions, such as the University of Texas System, also play a crucial role in early-stage discovery and patenting.
Impact of Patent 5,881,926 on the Landscape
Patent 5,881,926 contributes to the landscape by:
- Defining a Specific Prodrug Class: It provides a foundational patent for a particular approach to improving antiviral drug delivery, particularly for guanine derivatives and related heterocycles.
- Blocking Competitors: It prevents other entities from making, using, selling, or importing prodrugs that fall within the scope of its claims, particularly those targeting the specified viral infections.
- Licensing Opportunities: For entities developing guanine-based antivirals or similar heterocyclic compounds, this patent presents potential licensing requirements or opportunities for co-development if their prodrug strategy aligns with or circumvents the patent's claims.
Freedom to Operate (FTO) Considerations
For companies developing antiviral therapies based on nitrogen-containing heterocycles, a thorough Freedom to Operate (FTO) analysis is essential. This involves:
- Mapping Existing Patents: Identifying all relevant patents, including those that have expired, are still in force, or are pending.
- Claim Analysis: Carefully analyzing the claims of active patents, such as 5,881,926, to determine if a proposed product or process infringes upon them.
- Circumvention Strategies: Designing new compounds or prodrug strategies that fall outside the scope of existing patent claims. This might involve using different promoieties, linkers, or targeting different classes of nitrogen-containing heterocycles.
- Invalidity Challenges: Assessing the validity of existing patents to potentially challenge their enforceability.
Patent Expiration and Generic Entry
Patent 5,881,926 has an expiration date related to its grant date. U.S. patents granted after June 8, 1995, generally have a term of 20 years from the date on which the application was filed. Given the March 16, 1999 grant date, its filing date was likely in the mid-to-late 1990s.
- Projected Expiration: If the filing date was, for example, March 16, 1997, the patent would expire on March 16, 2017. If the filing date was later, the expiration date would be later. This information is crucial for generic manufacturers looking to enter the market.
- Market Impact: Upon expiration, the patent's claims no longer prevent generic versions of the specific prodrugs covered from being manufactured and sold, potentially leading to increased market competition and reduced drug prices.
Technological Trends and Future Developments
The field of antiviral prodrugs continues to evolve. Current research trends include:
- Targeted Delivery: Developing prodrugs that are specifically activated at the site of infection or within infected cells, reducing systemic toxicity.
- Nucleotide/Nucleoside Analogs: Continued development of novel nucleotide and nucleoside analogs that are prodrugs.
- Combination Therapies: Designing prodrugs that can be co-administered with other antiviral agents, potentially overcoming resistance mechanisms.
- Small Molecule Inhibitors: Expanding prodrug strategies beyond nucleoside analogs to other classes of antiviral small molecules.
Key Takeaways
- Patent 5,881,926 protects prodrugs of nitrogen-containing heterocyclic compounds for treating viral infections, with specific claims covering guanine derivatives and their use in treating herpesviruses, HIV, and hepatitis B.
- The patent's claims define the chemical structure of the prodrug, the cleavable linker, and the promoiety, as well as methods of treatment and bioavailability enhancement.
- The patent landscape is competitive, necessitating thorough Freedom to Operate analyses for new antiviral prodrug development.
- The expiration of this patent opens opportunities for generic competition, provided no other patents or regulatory exclusivities are in place.
- Ongoing research focuses on targeted delivery, novel analogs, and combination therapies, shaping the future of antiviral prodrug development.
Frequently Asked Questions
-
What specific antiviral drugs are covered by the base structure of Patent 5,881,926?
The patent protects prodrugs of "nitrogen-containing heterocyclic compounds of Formula I." While Formula I is defined generally, claims 2 and 3 specifically mention that the compound is a purine derivative, with claim 3 narrowing it to guanine or a derivative thereof. Therefore, the patent primarily targets prodrugs of guanine-based antiviral agents.
-
When did United States Patent 5,881,926 expire?
U.S. patents granted after June 8, 1995, have a term of 20 years from the filing date. To determine the exact expiration date of U.S. Patent 5,881,926, the filing date of the application would need to be consulted. Assuming a filing date in the mid-to-late 1990s, the patent would likely have expired in the late 2010s.
-
Does this patent cover all prodrugs of antiviral nitrogen-containing heterocycles, or is it limited in scope?
The patent's scope is limited by its specific claims. It protects prodrugs that meet the defined chemical structure (R1-L-R2) where R1 is a nitrogen-containing heterocycle, L is a cleavable linker, R2 is a promoiety, and the prodrug is convertible in vivo. Claims 2-8 further narrow the scope to specific types of heterocycles (purines, guanine), linkers (ester, ether), and promoieties (amino acids, peptides). Therefore, it does not cover all possible prodrugs of all antiviral nitrogen-containing heterocycles.
-
What are the implications of this patent for generic drug manufacturers?
If the patent is still in force, generic manufacturers cannot produce, use, or sell prodrugs that fall within its claims without a license. Once the patent expires, the claims expire, allowing generic manufacturers to produce and market equivalent prodrugs, provided no other patents or regulatory exclusivities are in place.
-
Are there any known antiviral drugs currently on the market that are based on the prodrug technology described in Patent 5,881,926?
While this patent describes a general prodrug strategy, its specific claims would need to be matched against existing drug structures. Guanine-based prodrugs have been developed for antiviral therapy. For instance, famciclovir is a prodrug of penciclovir (a guanine analog), and valacyclovir is a prodrug of acyclovir (a guanine analog). Whether these specific marketed drugs infringe or are covered by the claims of Patent 5,881,926 would require detailed claim analysis and comparison to their chemical structures and prodrug moieties.
Citations
[1] The Board of Regents of the University of Texas System. (1999). Prodrugs of nitrogen-containing heterocycles (U.S. Patent No. 5,881,926). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
